Skip to content
obesity
-
Eli Lilly expands partnership with Nimbus Therapeutics to develop oral weight loss drug
Nimbus will leverage its specialized expertise in computational chemistry and structure-based drug design to discover a small molecule drug candidate.
-
Mayo Clinic develops a genetic test to personalize the response to weight loss medication
The innovative test measures a biological feature known as “calories to satiation” (CTS), which refers to the amount of food a person needs to feel full.
-
Pfizer strengthens obesity drug pipeline with USD2B licensing deal with YaoPharma
YaoPharma stands to earn as much as USD1.94 billion in additional milestone payments tied to development, regulatory, and commercial achievements.
-
WHO endorses GLP-1 receptor agonists for obesity treatment, urges expanded access
The guidance comes as more than one billion people worldwide currently live with obesity, a number projected to double by 2030 without decisive intervention.